



Q4 FY26 Investor Presentation

Tuesday 14 July 2026



Disclaimer

This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or

representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward-looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Orthocell at a Glance

Australian medical technology company with growing international revenue driven by the commercialisation of its flagship nerve repair product, Remplir™, in the ~US\$2 billion U.S. market¹.



Fully funded and investing in sales growth


\$44 million in cash reserves², no financial debt³ and no royalty liabilities to execute sales growth strategy.



Remplir U.S. strategy on track with continued global expansion

Remplir U.S. key commercial metrics demonstrating strong growth with sales continuing to build.

EU/UK clearance expected 2H CY26.



US\$3.5 billion¹ global nerve repair market

Approved and now selling in AUS, NZL, USA, CAN, SGP, HKG and THA.

Company anticipating a material uplift in U.S. revenue in the upcoming quarters.

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies.
2. AU\$44.1M as of 30 June 2026, this includes \$9.4 million in cash and cash equivalents and \$34.7 million in security and term deposits with maturities ranging from 3 to 12 months.
3. No long-term secured debt facilities. The Company maintains a short-term premium funding facility used to finance insurance premiums, repaid within the policy period.

Key highlights for the quarter ended 30 June 2026

Another very strong quarter, driven by continued execution across all key growth drivers, with U.S. momentum building as Remplir™ expands its commercial footprint and outperforms expectations alongside sustained Australian growth.



Win in the Americas

Continue growth
in ANZ and Asia

Build global
footprint

Advance the
product pipeline



June Quarter Operational Highlights

- Commercialisation of Remplir in the US continues to track ahead of expectations
- Distributor network expanded to 20+ states and ~50% of the U.S. population
- Appointment of a Thai distributor for Remplir, strengthening our Asia-Pacific commercial footprint
- Continued adoption of Remplir in Australia with strong growth for the quarter
- Remplir global humanitarian reach expanded through an initiative delivering Remplir to victims of war in Ukraine
- Remplir UK / EU market access program progressing according to schedule
- Remplir nerve sparing prostate cancer surgery commercial opportunity gathers momentum
- Commencement of U.S. FDA regulatory program for SmrtWrap™ tendon repair application

Key performance metrics

Record revenue of \$13.2 million for FY26, up 44% on the prior financial year, and \$3.8 million for the June quarter, an increase of 20% on the March quarter, with Q4 FY26 delivering record quarterly revenue and strong performance across all six key metrics, extending a three-year track record of consistent commercial growth.



1. FY26 Revenue

A\$13.2M

⬆️ 44% growth YoY



2. Q4 FY26 Revenue

A\$3.8M


⬆️ 20% growth QoQ



3. Funds Available¹

A\$44.1M

⬆️ 4.6 years cash runway²



4. Q4 FY26 Revenue (Remplir™ U.S.)

A\$0.33M

⬆️ 10% growth QoQ



5. Cumulative Hospitals³ (Remplir U.S.)

70

⬆️ 27% growth QoQ



6. Cumulative Surgeons³ (Remplir U.S.)

76

⬆️ 55% growth QoQ

1. Funds Available of AU\$44.1M as of 30 June 2026, this includes \$9.4 million in cash and cash equivalents and \$34.7 million in security and term deposits with maturities ranging from 3 to 12 months.

2. Cash runway is calculated as Funds Available divided by annualised 4Q 2026 normalised operating cash burn.

3. Cumulative hospitals and surgeons is the total cumulative number of individual hospitals and surgeons that have purchased one or more units of Remplir.

4. Growth percentages are calculated on unrounded figures and may differ slightly from recalculations based on rounded numbers shown.



Revenue and cash flow performance


Jim Piper
Chief Financial Officer




Quarterly and FY26 revenue growth

U.S. Remplir™ sales continue to grow quarter on quarter, with \$0.33M revenue for Q4 FY26, \$0.92M since launch and Remplir contributing the vast majority of the 44% year-on-year growth for Orthocell

Total Revenue¹ by Quarter (A\$M)



Revenue Bridge: FY25 to FY26 (A\$M)



1.Revenue includes product sales, sundry, licensing, grant and interest income (excludes R&D tax refund recorded as income)

2.Excluding US Remplir Sales where applicable.

3.Growth percentages are calculated on unrounded figures and may differ slightly from recalculations based on rounded numbers shown.

Quarterly cash flow summary

Sustainable cash reserves are in place to fund the commercialisation of Remplir™ and support the business to cash flow breakeven, with no additional funding required

AUD \$M	FY26	4Q FY26	3Q FY26	VAR ¹
Receipts from customers	7.6	2.5	1.6	0.9
Payments to suppliers and employees	(25.3)	(6.6)	(4.9)	(1.7)
Government grants & net interest received	4.9	0.5	3.4	(2.9)
Operating cash burn for the period²	(12.7)	(3.6)	0.1	(3.7)
Annual R&D tax refund ³	(3.0)	-	(3.0)	3.0
Non-recurring expenditure (ERP, Automation, Prepaid and other one-offs)	3.3	1.2	0.4	0.8
Normalised operating cash burn⁴	(12.4)	(2.4)	(2.5)	0.1
Capital expenditure & other investments	(2.3)	(1.0)	(1.2)	0.2
Proceeds from fund raising and other financing	30.5	0.8	(0.1)	0.9
Funds Available⁵	44.1	44.1	48.0	(3.9)
Cash & cash equivalents	9.4	9.4	7.8	1.6
Term deposits between 3-12 months maturity	34.7	34.7	40.2	(5.5)

Net operating cash is inline with expectations, increased receipts from growth in quarterly revenues from previous quarters and increase of operating expenditure due increased production and timing.

Normalised operating cash burn is constant quarter on quarter after accounting for the R&D tax incentive rebate, investment in the ERP (NetSuite), automation of processing and other one-off activities.

Capital expenditure & other investments are consistent with equity raising use of funds to increase equity position in Marine Biomedical and capital projects to increase the manufacturing capacity. All capital projects are on time and budget and will continue through FY27.

Funds Available of \$44.1 million provide a strong liquidity position and sufficient cash runway to support capital works, commercial execution and R&D activities through to anticipated breakeven.

1. VAR represents the variance between 4Q 2026 and 3Q 2026.

2. Numbers may not sum due to rounding.

3. The R&D tax incentive refund is received annually, resulting in nil/lump sum amounts in individual quarters.

4. Normalised operating cash burn is a non-IFRS, unaudited measure that excludes the annual R&D tax incentive refund and non-recurring expenditure (ERP, automation, prepayments and other one-offs).

5. Funds Available comprises cash and cash equivalents, security deposits, and term deposits with maturity greater than 3 months.



U.S. Remplir™ launch update

John Walker


Vice President of U.S. Sales



Remplir™ significant U.S. market opportunity

We are targeting 10% of the 700,000¹ US Peripheral nerve repair procedures every year, with Orthocell cash breakeven at ~6,000 procedures

700,000
US Peripheral
nerve repair
procedures
every year.



Targeting 10%, with
an initial focus on
5% of the market

 ~ **60,000**
Devices³

 **35,000**
Procedures

Breakeven²

 ~ **10,000**
Devices³

 ~ **6,000**
Procedures

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both US and OUS databases and studies.

2. Breakeven is cash breakeven and reflects the point at which net operating cash flow is zero, based on current pricing and cost assumptions.

3. ~1.7 units per procedure, Average units per procedure reflects observed utilisation from available data, supplemented by clinical assumptions regarding standard use per operation.

FY26 U.S. Remplir™ commercialisation performance

Commercialisation of Remplir in the U.S. continues to track ahead of expectations



50%

Distributor Coverage
(coverage of U.S. population)

Distributor coverage exceeded targets by 25%, with 18 distributors now covering approximately 50% of the U.S. population across 20+ states on the East and West coasts.



70

Cumulative Hospitals¹
(total cumulative)

Hospitals purchasing Remplir reached 70, with over 100 VAC approvals submitted, in process or approved, reflecting strong early adoption.



76

Cumulative Surgeons¹
(total cumulative)


76 surgeons have purchased one or more units of Remplir, supported by strong surgeon feedback, exceeding initial expectations.

1. Cumulative hospitals and surgeons is the total cumulative number of individual hospitals and surgeons that have purchased one or more units of Remplir.

U.S. Remplir™ commercial momentum is building


Exceptional early growth since the first sale of Remplir on 26 June 2025

U.S. Remplir Hospitals Cumulative by Quarter¹




Hospitals have grown to 70 in just over a year (26th June, first sale), representing a +189% CQGR² and strong growth in hospital access

U.S. Remplir Surgeons Cumulative by Quarter¹



Surgeons have grown to 76 in just over a year (26th June, first sale), representing a +195% CQGR² and strong growth in clinical adoption

U.S. Remplir Unit Sales by Quarter



Unit Sales have grown to 119 per quarter in just a year (26th June, first sale), representing +230% CQGR² and strong sales growth

1. Number of Hospitals and Surgeons as at 30 June, 2026
2. CQGR = compound quarterly growth rate

FY27 U.S. Remplir™ commercialisation targets

As commercial penetration continues to build, Orthocell is positioned for a material uplift in U.S. revenue



80%

Distributor Coverage
(coverage of U.S. population)

Work with our distributor partners to increase our state coverage and create more experts in the field. We are targeting 80% distributor coverage of the US population, covering 30+ states.



100-150

Cumulative Hospitals¹
(total cumulative)

Continue to open new accounts through the submission of Value Assessment Committee (VAC) approvals, with a target of 100-150 hospitals with one or more device sales.



150-200

Cumulative Surgeons¹
(total cumulative)

Surgeon on-boarding through education, product demonstration and clinical efficacy, with a target of 150-200 surgeons with one or more device sales.

1. Cumulative hospitals and surgeons is the total cumulative number of individual hospitals and surgeons that have purchased one or more units of Remplir.



Other achievements and upcoming catalysts



Achievements and upcoming catalysts¹



RemplirTM | Nerve repair, made SMRT



Foundations in place for U.S. growth	Achieved
Appoint first and second distributors in CAN	Achieved
Appoint exclusive distributor in HKG	Achieved
HK first surgical use	Achieved
EU+UK submissions lodged	Achieved
FY25 R&D tax refund (\$3M)	Achieved
Appoint exclusive distributor in UK	Achieved
First sale in Canada	Achieved
Appoint THA distributor	Achieved

<i>Initial prostate patient data</i>	2H CY26
<i>EU+UK market clearance</i>	2H CY26
<i>SmrtWrap Tendon US Pre-Submission</i>	2H CY26

1. Timelines may be subject to change due to circumstances not under the Company’s control

Q&A





Authorised for release by
The Board of Directors of Orthocell Limited

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

orthocell.com